See the DrugPatentWatch profile for qulipta
Qulipta is expected to go generic in 2030. This is based on the expiration of its primary patents.
When does Qulipta's exclusivity expire?
Qulipta's (atogepant) most significant patent is scheduled to expire in 2030. This patent is crucial for maintaining market exclusivity for the drug [1].
What does "going generic" mean for Qulipta?
When Qulipta goes generic, it means that other pharmaceutical companies will be able to produce and sell their own versions of the drug. These versions will be called biosimilars or generics and will be chemically identical to Qulipta. This typically leads to a significant decrease in the drug's price [1].
How does Qulipta's patent expiration compare to other migraine treatments?
Qulipta, an oral CGRP inhibitor, entered a market with other treatments for episodic migraine. Its patent expiration timeline is a key factor in the competitive landscape of migraine therapies. The development of oral CGRP inhibitors like Qulipta was a significant advancement for patients seeking less invasive treatment options compared to injectable CGRP antibodies [2].
What is the active ingredient in Qulipta and what is it used for?
The active ingredient in Qulipta is atogepant. It is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the preventive treatment of episodic migraine in adults [2].
Where can I find more information on drug patent expirations?
For detailed information on drug patent expirations, including those for Qulipta, resources like DrugPatentWatch.com can provide comprehensive data [1].